Keywords: Novo Nordisk, Vitoza, Januvia, Merck & Co, Tpe 2 diabetes

Novo Nordisk reports new data demonstrating superior efficacy of Victoza over Januvia in type 2 diabetes

Article | 23 April 2010

Print This

The first head-to-head study comparing Danish drugmaker Novo Nordisk’s new once-daily human GLP-1 analog Victoza (liraglutide) with a DPP-4 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in